PsyBio Therapeutics Corp. (PSYBF)
USD 0.0
(-98.0%)
USD 0.0
(-98.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | 4.4 Million USD | -51.01% |
| 2021 | 9.6 Million USD | 95.99% |
| 2020 | 4.9 Million USD | 12476.93% |
| 2019 | 38.96 Thousand USD | 86.8% |
| 2018 | 20.86 Thousand USD | -47.65% |
| 2017 | 39.85 Thousand USD | -48.27% |
| 2016 | 77.04 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 788.97 Thousand USD | -16.7% |
| 2023 Q2 | 131.99 Thousand USD | -83.27% |
| 2022 Q2 | 1.36 Million USD | -7.22% |
| 2022 Q4 | 947.15 Thousand USD | 3.8% |
| 2022 FY | 4.7 Million USD | -51.01% |
| 2022 Q1 | 1.47 Million USD | -33.83% |
| 2022 Q3 | 912.5 Thousand USD | -33.39% |
| 2021 FY | 9.6 Million USD | 95.99% |
| 2021 Q1 | 1.4 Million USD | 20882.88% |
| 2021 Q2 | 3.82 Million USD | 172.01% |
| 2021 Q3 | 2.32 Million USD | -39.21% |
| 2021 Q4 | 2.23 Million USD | -4.03% |
| 2020 Q2 | 24.51 Thousand USD | 2371.61% |
| 2020 FY | 4.9 Million USD | 12476.93% |
| 2020 Q4 | 6701.12 CAD | -98.23% |
| 2020 Q3 | 379.19 Thousand USD | 1446.51% |
| 2020 Q1 | 992.03 USD | -90.6% |
| 2019 Q4 | 10.55 Thousand CAD | 0.0% |
| 2019 FY | 38.96 Thousand USD | 86.8% |
| 2018 FY | 20.86 Thousand USD | -47.65% |
| 2017 FY | 39.85 Thousand USD | -48.27% |
| 2016 FY | 77.04 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -230.131% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 12.562% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 85.082% |
| Nascent Biotech, Inc. | 2.22 Million USD | -97.709% |
| Rebus Holdings, Inc. | 664 Thousand USD | -563.957% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 88.166% |
| Qrons Inc. | 643.67 Thousand USD | -584.92% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -1031.688% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 92.325% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -961.106% |
| Skye Bioscience, Inc. | 13.54 Million USD | 67.458% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 94.92% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 10.355% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1584.461% |
| SQZ Biotechnologies Company | 85.61 Million USD | 94.851% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -51.177% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -193.54% |
| Mesoblast Limited | 5.9 Million USD | 25.302% |
| Marizyme, Inc. | 19.23 Million USD | 77.086% |
| Genus plc | 147.7 Million USD | 97.015% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 49.783% |
| Pharming Group N.V. | 225.49 Million USD | 98.045% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -115.193% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -228.626% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 47.132% |
| ContraFect Corporation | 56.88 Million USD | 92.25% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -198.135% |
| IMV Inc. | 37.7 Million USD | 88.309% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -57.997% |
| MultiCell Technologies, Inc. | 567.42 USD | -776868.031% |
| ONE Bio Corp. | 6.44 Million USD | 31.584% |
| Accustem Sciences Inc. | 3.74 Million USD | -17.677% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 94.87% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -728.757% |
| Q BioMed Inc. | 3.43 Million USD | -28.285% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 82.162% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -67.788% |
| Biomind Labs Inc. | 994.18 Thousand USD | -343.447% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 95.562% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -150.539% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 34.375% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -136.47% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 17734.688% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 72.463% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -140.242% |
| GB Sciences, Inc. | 1.42 Million USD | -210.359% |
| Alpha Cognition Inc. | 9.7 Million USD | 54.576% |
| HST Global, Inc. | 140.9 Thousand USD | -3028.781% |
| CSL Limited | 3.44 Billion USD | 99.872% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -291.913% |
| Halberd Corporation | 74.84 Thousand USD | -5790.639% |
| Enzolytics Inc. | 2.17 Million USD | -102.278% |
| Agentix Corp. | 1.37 Million USD | -221.389% |
| Resverlogix Corp. | 12.71 Million USD | 65.319% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -20.762% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.713% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -322.287% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -83.318% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -179.144% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -29.477% |
| AVAX Technologies, Inc. | 7.31 Million USD | 39.692% |
| Zenith Capital Corp. | 8.94 Million USD | 50.703% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.466% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -25206.653% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -79.556% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2470.519% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -129.51% |
| Kadimastem Ltd | 2.41 Million USD | -82.924% |
| Helix BioMedix, Inc. | 1.97 Million USD | -123.56% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 59.431% |
| BioStem Technologies, Inc. | 22.97 Million USD | 80.811% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -2329.221% |
| LadRx Corporation | 3.81 Million USD | -15.659% |
| Cell Source, Inc. | 4.32 Million USD | -1.926% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -377.382% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -377.382% |
| NovAccess Global Inc. | 2.46 Million USD | -78.723% |
| Affymax, Inc. | 39.38 Million USD | 88.806% |
| Itoco Inc. | 919.14 Thousand USD | -379.65% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -4.017% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -293.983% |
| Mobile Lads Corp. | 554.54 Thousand USD | -695.006% |
| CytoDyn Inc. | 18.05 Million USD | 75.586% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -17416.278% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1903.232% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -210.515% |
| SYBLEU INC | 160.87 Thousand USD | -2640.416% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -142.726% |
| International Stem Cell Corporation | 5.27 Million USD | 16.36% |
| Bioxytran, Inc. | 3.82 Million USD | -15.406% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -8274.819% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -21571.691% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 87.844% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -172.477% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -499.139% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -41.712% |
| Neutra Corp. | 243.82 Thousand USD | -1708.159% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 74.746% |
| PureTech Health plc | 144.59 Million USD | 96.951% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 78.484% |
| IXICO plc | 4.7 Million USD | 6.338% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 49.884% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 96.256% |
| CSL Limited | 3.89 Billion USD | 99.887% |
| Cellectis S.A. | 97.32 Million USD | 95.47% |